Back to Journals » Drug Design, Development and Therapy » Volume 5

Future prospects in the treatment of erectile dysfunction: focus on avanafil

Authors Alwaal A, Al-Mannie, Carrier S

Published 18 October 2011 Volume 2011:5 Pages 435—443

DOI https://doi.org/10.2147/DDDT.S15852

Review by Single-blind

Peer reviewer comments 2


Amjad Alwaal, Raed Al-Mannie, Serge Carrier
Division of Urology, McGill University Health Centre, Montreal, Quebec, Canada

Abstract: The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 phosphodiesterase (PDE5) inhibitors. Their efficacy, safety, and ease of administration have made them first-line treatment for ED. This article reviews the current therapies available for ED, and the new PDE5 inhibitors that are being investigated. Furthermore, it examines all the current ED treatment options that are in different phases of development (including oral and topical pharmacotherapy, gene therapy, and tissue engineering). A special emphasis is on avanafil, a new PDE5 inhibitor that has been studied extensively in Phase I and II clinical trials and has undergone several Phase III trials. Avanafil is a promising medication for ED due to its favorable pharmacokinetics, safety, and efficacy.

Keywords: PDE5, sexual performance, pharmacokinetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]